How Much K2 Should I Take Daily for Osteoporosis?

Most clinical trials studying vitamin K2 for bone health have used one of two forms at very different doses: MK-7 (menaquinone-7) at roughly 180 to 375 micrograms per day, or MK-4 (menaquinone-4) at 45 milligrams per day. There is no single universally agreed-upon dose, and no major Western regulatory body has established vitamin K2 as a standalone osteoporosis treatment. Japan, however, has approved MK-4 at the pharmacological dose of 45 mg/day for treating osteoporosis. The answer to “how much” depends heavily on which form of K2 you take, what you expect it to do, and what other nutrients and medications are in the picture.

Two Forms, Two Completely Different Dose Ranges

Vitamin K2 is not a single molecule. The two forms you will encounter in supplements are MK-4 and MK-7, and they behave differently in your body. MK-4 is poorly absorbed at nutritional-level doses and clears from the blood quickly. MK-7, by contrast, is well absorbed even in small amounts and stays in circulation much longer.

A head-to-head comparison in healthy women confirmed this gap: MK-4 was barely detectable in blood after a nutritional dose, while MK-7 showed up clearly and lingered.

This pharmacokinetic difference explains why MK-4 trials typically use milligram-level doses (often 45 mg/day), while MK-7 trials work in the microgram range (180–375 µg/day). Both forms also differ structurally from vitamin K1 (phylloquinone), found in leafy greens, in ways that affect how they are distributed through the body and taken up by different tissues.

What MK-7 Trials Have Found

The strongest MK-7 evidence comes from a handful of randomized, placebo-controlled trials in postmenopausal women, most lasting one to three years. Results are promising in some respects, but more mixed than supplement marketing suggests.

A three-year Dutch trial gave 180 µg/day of MK-7 to healthy postmenopausal women. It significantly slowed bone mineral content and bone mineral density loss at the lumbar spine and femoral neck, and improved markers of bone strength, including a reduction in the loss of vertebral height in the lower thoracic spine.

A separate 12-month trial used a higher dose of 375 µg/day in postmenopausal women with osteopenia. It did not find significant differences in standard bone density measurements at any site. However, detailed imaging of bone microarchitecture at the shin bone (tibia) told a different story: the MK-7 group maintained its trabecular bone structure, while the placebo group lost trabeculae and showed wider spacing between remaining ones. The researchers interpreted this as evidence that MK-7 preserves the internal scaffolding of bone even when the conventional density scan does not register a change.

⁴

A longer three-year follow-up of similar women at 375 µg/day, though, found no significant differences between MK-7 and placebo in bone density at the hip, femoral neck, or lumbar spine, and bone turnover markers were similarly unchanged between groups.

⁵

So MK-7 may help maintain bone microarchitecture and slow some measures of bone loss, but its ability to clearly move the needle on bone density scans remains unproven.

A Chinese trial tested a lower dose of 90 µg/day of MK-7 in middle-aged and elderly participants and found that postmenopausal women in the supplemented groups had significantly less bone loss at the femoral neck compared with placebo. Men in the same trial, however, saw no benefit.

⁶

What MK-4 Trials Have Found

MK-4 research looks very different because the doses are so much larger. In Japan, 45 mg/day of MK-4 (menatetrenone) is an approved treatment for osteoporosis.

⁷

A three-year trial of 325 postmenopausal women given 45 mg/day of MK-4 found that while standard bone density measurements did not change compared with placebo, bone mineral content and the width of the femoral neck increased, and hip bone strength was maintained over the study period instead of declining as it did in the placebo group.

⁸

An important dose-response study tested whether all those milligrams are really necessary. In postmenopausal women with osteoporotic fractures, just 0.5 mg/day of MK-4 cut undercarboxylated osteocalcin (a marker of vitamin K insufficiency in bone) by half. Stepping up to 5 mg/day halved it again. But going to 45 mg/day offered no further improvement over the 5 mg dose.

⁹

This is a genuinely interesting finding. It suggests that for the specific biological job of activating osteocalcin, 5 mg/day of MK-4 may be enough. Whether the 45 mg dose does something additional beyond osteocalcin activation, like influencing other bone-health pathways, is still debated.

How K2 Actually Works in Bone

Vitamin K2 does not build bone directly the way calcium provides raw building material. Instead, it acts as a helper for an enzyme that activates several bone-related proteins. The most studied of these is osteocalcin, a protein made by bone-building cells. Osteocalcin needs to have a chemical modification, called carboxylation, before it can bind calcium and help regulate how minerals are deposited in bone.

¹⁰

Without enough vitamin K, osteocalcin stays in its inactive, undercarboxylated form and cannot do its job properly. High blood levels of undercarboxylated osteocalcin are associated with increased fracture risk.

¹¹

Lab studies have shown that vitamin K2 boosts the accumulation of carboxylated osteocalcin in the space between bone cells, which in turn promotes mineralization.

¹²

Another vitamin K-dependent protein, matrix Gla protein (MGP), plays a different but related role: it inhibits calcification in arteries rather than promoting it in bone. This dual action is part of why K2 has drawn interest for both bone and cardiovascular health.

¹³

Why Vitamin D and K2 Are Often Paired

You will rarely find a K2 supplement that does not also mention vitamin D, and there is a biological reason. Vitamin D promotes the production of several vitamin K-dependent proteins, including osteocalcin and MGP. But producing those proteins is only half the job; they need to be carboxylated by vitamin K before they can function. Taking vitamin D without adequate vitamin K could, in theory, increase the pool of inactive proteins sitting around in your body.

¹⁴

Clinical data supports this pairing. A study of postmenopausal women with osteoporosis compared calcium alone, vitamin D3 alone, vitamin K2 alone, and the combination of D3 plus K2. The combined group saw a significantly greater increase in lumbar spine bone density than any of the single-nutrient groups or the calcium-only control.

¹⁵

A separate 24-month trial found that the D3 plus K2 combination increased bone density by roughly 5%, while K2 alone barely moved it.

¹⁶

These results suggest that K2 supplementation works best as part of a broader nutrient strategy rather than in isolation. Most bone-health researchers now view K2, vitamin D, and calcium as a package deal rather than standalone interventions.

Safety, Side Effects, and the Warfarin Problem

Vitamin K2 has a remarkably clean safety profile at the doses used in studies. The World Health Organization and the Food and Agriculture Organization have not established a tolerable upper intake level for vitamin K2, specifically because adverse effects in healthy people have been too rare to set one.

¹⁷

A meta-analysis looking at MK-4 for postmenopausal osteoporosis did note that the vitamin K2 groups had a slightly higher rate of minor adverse reactions than placebo, but no serious events were linked to the supplement.

¹⁸

The major safety concern is the interaction with warfarin and similar blood-thinning medications. Warfarin works by blocking the recycling of vitamin K, which reduces clotting. But it also blocks the activation of proteins like MGP outside the liver, which is why long-term warfarin use is associated with vascular calcification.

¹⁹

Adding vitamin K2 supplements while on warfarin can directly counteract the drug’s anticoagulant effect. Modeling data from patients undergoing catheter ablation showed that MK-4 doses above 20 mg caused a measurable decrease in INR, the standard measure of how well warfarin is working.

²⁰

Even lower doses of MK-7 could be problematic, since MK-7’s long half-life means it accumulates in the blood over days. If you take warfarin or another vitamin K antagonist, do not start K2 supplements without your prescriber’s involvement. Some clinicians are exploring the idea of co-supplementing small, stable K2 doses alongside adjusted warfarin to protect against vascular calcification, but this is not standard practice.

Food Sources and Whether They Are Enough

Typical dietary intakes of vitamin K fall below the levels associated with better bone density and reduced fracture risk.

²¹

The richest food source of MK-7 by a wide margin is natto, the Japanese fermented soybean dish. A standard serving of natto can contain several hundred micrograms of MK-7. Studies comparing regions of Japan where natto is eaten regularly versus rarely found dramatically higher blood levels of MK-7 and more active osteocalcin in frequent natto eaters.

²²

Controlled feeding studies confirmed this: when volunteers ate natto containing progressively higher MK-7 content, their blood MK-7 levels rose correspondingly, and levels of undercarboxylated osteocalcin dropped, meaning more of their bone-building protein was in its active form.

²³

Other fermented foods and animal products contain K2 as well, including certain aged cheeses, egg yolks, and organ meats, but the amounts are modest compared to natto. If you eat natto regularly, you may be getting enough MK-7 without a supplement. Most people outside Japan, however, consume very little K2 from food.

Your Gut Bacteria Contribute Too

Some vitamin K2 is produced by bacteria in your large intestine. Certain gut bacterial groups, particularly Bacteroides species, are associated with higher vitamin K2 levels. A study of postmenopausal Japanese women found that those with a higher proportion of Bacteroides in their gut had significantly higher K2 levels and a substantially lower history of fractures.

²⁴

However, the amount of K2 your gut bacteria produce and how much you actually absorb from the colon is not well quantified. Absorption of vitamin K2 in the intestine depends on the presence of bile salts and fats, and the colon, where most bacterial K2 production occurs, is less efficient at absorbing fat-soluble vitamins than the small intestine.

²⁵

Relying on gut bacteria alone is unlikely to produce the amounts used in clinical trials. Still, the connection between gut health and bone metabolism is drawing increasing research interest and may eventually inform more personalized supplementation strategies.

Why the Standard Bone Density Scan Can Be Misleading

One of the frustrating aspects of K2 research is that the most commonly used outcome, the DXA bone density scan, may not capture what K2 is doing. Several of the trials above found no difference in DXA-measured bone density between K2 and placebo groups, yet did find preservation of bone microarchitecture, maintenance of bone geometry, or improvements in bone strength indices. The 375 µg/day MK-7 trial is the clearest example: no DXA difference, but significantly preserved trabecular structure at the tibia.

⁴

Similarly, the MK-4 hip geometry trial showed unchanged DXA-BMD but increased bone mineral content and maintained bone strength.

⁸

Bone quality and bone density are not the same thing. A honeycomb with more cross-links is stronger than one with fewer, even if they weigh the same on a scale. K2’s effects may be more about quality than quantity, which standard clinical imaging is not always set up to detect. This does not mean K2 “works and doctors just can’t see it” — it means the evidence is genuinely ambiguous, and you should not expect a clear bump on your next DXA scan from adding K2 alone.

Absorption Tips

Both MK-4 and MK-7 are fat-soluble, which means they need dietary fat to be absorbed properly. Taking a K2 supplement on an empty stomach or with a fat-free meal reduces how much reaches your bloodstream. Research on intestinal vitamin K2 absorption has shown that bile salts and unsaturated fatty acids significantly increase uptake, while low-fat conditions slow it down.

²⁵

In practical terms, take your K2 with a meal that includes some fat. It does not need to be a large amount — a handful of nuts, some olive oil on a salad, or eggs will do. Some supplements come formulated in oil-based softgels, which helps with this automatically.

Does K1 From Leafy Greens Do the Same Job?

The short answer is: probably not, at least not for bone. A trial supplementing older men and women with phylloquinone (vitamin K1) at a dose achievable from food, alongside calcium and vitamin D, found no additional benefit to bone density at the spine or hip compared with calcium and D alone.

²⁶

K1 and K2 share the same core function in the clotting cascade, but they differ in how well they reach non-liver tissues. K2 forms, especially MK-7, are distributed more broadly to bone, arteries, and other peripheral tissues.

Eating your greens is still valuable for many reasons, but relying on K1 alone to protect your bones is not well supported by the clinical data.

Chronic Kidney Disease Complicates Things

People with chronic kidney disease (CKD) face a unique version of the vitamin K problem. CKD disrupts mineral and bone metabolism in complex ways, and vitamin K deficiency is common in this population. The calcification of blood vessels that accompanies kidney disease is partly driven by inactive MGP, the same protein that requires vitamin K for activation.

²⁷

Supplementing K2 in CKD patients is a growing area of research, but dosing, safety in the context of altered kidney function, and interactions with the many medications these patients take make it a situation where self-prescribing is genuinely risky. If you have kidney disease and are interested in K2, this is one of the clearer cases where working with a specialist is necessary rather than just advisable.